The present invention relates to: an activity modulator which is a means for modulating the activity of CD300b dependent phagocytosis； and medicine for the treatment or prevention of a disease or condition in which the activity is involved. The activity modulator comprises a CD300a binding agent and modulates CD300b dependent phagocytosis signals in a macrophage.
